Wells Fargo’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-747,822
| Closed | -$3.86M | – | 7003 |
|
|
2019
Q2 | $3.86M | Sell |
747,822
-202,179
| -21% | -$909K | ﹤0.01% | 2799 |
|
|
2019
Q1 | $3.42M | Buy |
950,001
+208,733
| +28% | +$905K | ﹤0.01% | 2901 |
|
|
2018
Q4 | $4.54M | Sell |
741,268
-5,806
| -0.8% | -$35.4K | ﹤0.01% | 2528 |
|
|
2018
Q3 | $4.36M | Buy |
747,074
+61,315
| +9% | +$306K | ﹤0.01% | 2750 |
|
|
2018
Q2 | $2.92M | Buy |
685,759
+46,323
| +7% | +$234K | ﹤0.01% | 3142 |
|
|
2018
Q1 | $2.82M | Buy |
639,436
+177,824
| +39% | +$793K | ﹤0.01% | 3100 |
|
|
2017
Q4 | $2.43M | Buy |
461,612
+94,247
| +26% | +$577K | ﹤0.01% | 3214 |
|
|
2017
Q3 | $2.25M | Buy |
367,365
+63,377
| +21% | +$401K | ﹤0.01% | 3204 |
|
|
2017
Q2 | $2.2M | Buy |
303,988
+27,836
| +10% | +$171K | ﹤0.01% | 3146 |
|
|
2017
Q1 | $1.46M | Buy |
276,152
+203,738
| +281% | +$1.38M | ﹤0.01% | 3453 |
|
|
2016
Q4 | $520K | Buy |
72,414
+44,717
| +161% | +$362K | ﹤0.01% | 4175 |
|
|
2016
Q3 | $259K | Sell |
27,697
-9,370
| -25% | -$77.8K | ﹤0.01% | 4327 |
|
|
2016
Q2 | $234K | Buy |
37,067
+5,092
| +16% | +$32.7K | ﹤0.01% | 4315 |
|
|
2016
Q1 | $176K | Buy |
31,975
+21,199
| +197% | +$79.7K | ﹤0.01% | 4483 |
|
|
2015
Q4 | $61K | Buy |
10,776
+700
| +7% | +$4.63K | ﹤0.01% | 5215 |
|
|
2015
Q3 | $85K | Buy |
10,076
+989
| +11% | +$16.7K | ﹤0.01% | 5000 |
|
|
2015
Q2 | $138K | Buy |
9,087
+7,308
| +411% | +$106K | ﹤0.01% | 4827 |
|
|
2015
Q1 | $29K | Buy |
1,779
+247
| +16% | +$4.39K | ﹤0.01% | 5242 |
|
|
2014
Q4 | $28K | Buy |
1,532
+209
| +16% | +$2.6K | ﹤0.01% | 5236 |
|
|
2014
Q3 | $13K | Sell |
1,323
-8,637
| -87% | -$105K | ﹤0.01% | 5489 |
|
|
2014
Q2 | $155K | Buy |
9,960
+1,951
| +24% | +$27.6K | ﹤0.01% | 4497 |
|
|
2014
Q1 | $149K | Buy |
8,009
+7,609
| +1,902% | +$152K | ﹤0.01% | 4475 |
|
|
2013
Q4 | $8K | Buy |
+400
| New | +$8.12K | ﹤0.01% | 5253 |
|
Other funds holding PETX
Wells Fargo's PETX Position: Q3 2019 in Review
Wells Fargo sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 747,822 shares — an estimated $3.86M sold.
Wells Fargo first reported a position in PETX in Q4 2013 and held it in 23 quarters. The position peaked at $4.54M in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Wells Fargo reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Wells Fargo sold 747,822 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $3.86M.
- Wells Fargo first reported a position in Aratana Therapeutics, Inc. in Q4 2013 and held it in 23 quarters.
- Wells Fargo's Aratana Therapeutics, Inc. position peaked at $4.54M in Q4 2018.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Wells Fargo's 13F filing for Q3 2019, filed 12 Nov 2019.